Advanced in Breast Cancer

Dr. Sarika Jain

Thoracic Surgery | General Surgery | Vascular Surgery
Faculty Physicians And Surgeons Of Llusm
12021 Jacaranda Ave, 
Hesperia, CA 
Advanced in Breast Cancer
Faculty Physicians And Surgeons Of Llusm
12021 Jacaranda Ave, 
Hesperia, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sarika Jain is a Thoracic Surgeon and a General Surgeon in Hesperia, California. Dr. Jain is rated as an Advanced provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Breast Cancer, Arterial Embolism, and Heart Bypass Surgery.

Her clinical research consists of co-authoring 20 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 17 articles and participated in 8 clinical trials in the study of Breast Cancer.

Specialties
Thoracic Surgery
General Surgery
Vascular Surgery
Licenses
Thoracic Surgery (Cardiothoracic Vascular Surgery) in CA
Hospital Affiliations
Providence St Mary Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D

Locations

FACULTY PHYSICIANS AND SURGEONS OF LLUSM
12021 Jacaranda Ave, Hesperia, CA 92345

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drugs: Endoxifen Hydrochloride, Tamoxifen Citrate
Study Phase: Phase 2
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
Enrollment Status: Completed
Publish Date: December 06, 2024
Intervention Type: Drug
Study Drugs: LEE-011, Fulvestrant
Study Phase: Phase 2
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes
Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes
Enrollment Status: Completed
Publish Date: June 12, 2024
Intervention Type: Biological, Other, Drug
Study Drugs: Nivolumab, Veliparib
Study Phase: Phase 1
A Phase II Window of Opportunity Trial of Ipilimumab and Nivolumab in Metastatic Recurrent HER2- Inflammatory Breast Cancer (IBC) The Win Trial
A Phase II Window of Opportunity Trial of Ipilimumab and Nivolumab in Metastatic Recurrent HER2- Inflammatory Breast Cancer (IBC) The Win Trial
Enrollment Status: Terminated
Publish Date: July 16, 2020
Intervention Type: Biological, Other
Study Phase: Phase 2
Phase II Study of Pembrolizumab and Capecitabine for Advanced Triple Negative and Hormone-Refractory Breast Cancer
Phase II Study of Pembrolizumab and Capecitabine for Advanced Triple Negative and Hormone-Refractory Breast Cancer
Enrollment Status: Unknown
Publish Date: July 13, 2020
Intervention Type: Other, Drug, Biological
Study Drugs: Capecitabine, Pembrolizumab
Study Phase: Phase 2
A Phase II, Open Label Study to Evaluate Denosumab in Patients With ER and/or PR-Positive, HER2-Negative Metastatic Breast Cancer (MBC) With Bone Metastases and Detectable Circulating Tumor Cells (CTCs)
A Phase II, Open Label Study to Evaluate Denosumab in Patients With ER and/or PR-Positive, HER2-Negative Metastatic Breast Cancer (MBC) With Bone Metastases and Detectable Circulating Tumor Cells (CTCs)
Enrollment Status: Terminated
Publish Date: November 20, 2018
Intervention Type: Biological, Other
Study Phase: Phase 2
View 8 Less Clinical Trials

20 Total Publications

Intracardiac echocardiography from coronary sinus.
Intracardiac echocardiography from coronary sinus.
Journal: Journal of cardiovascular electrophysiology
Published: July 08, 2022
Similar Doctors
Distinguished in Breast Cancer
Dr. Lisa D. Yee
General Surgery | Surgical Oncology
Distinguished in Breast Cancer
Dr. Lisa D. Yee
General Surgery | Surgical Oncology

City Of Hope Medical Foundation

1500 E Duarte Rd, 
Duarte, CA 
 (46.9 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lisa Yee is a General Surgeon and a Surgical Oncologist in Duarte, California. Dr. Yee is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, Oophorectomy, and Mastectomy.

Elite in Breast Cancer
Dr. John H. Yim
General Surgery | Surgical Oncology
Elite in Breast Cancer
Dr. John H. Yim
General Surgery | Surgical Oncology

City Of Hope Medical Foundation

Irvine, CA 
 (61.6 miles away)
949-671-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John Yim is a General Surgeon and a Surgical Oncologist in Irvine, California. Dr. Yim is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. His top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Thyroid Cancer, Mastectomy, and Thyroidectomy.

Elite in Breast Cancer
Dr. Dennis R. Holmes
General Surgery | Surgical Oncology
Elite in Breast Cancer
Dr. Dennis R. Holmes
General Surgery | Surgical Oncology
1505 Wilson Terrace, Suite 370, 
Glendale, CA 
 (59.5 miles away)
818-539-1985
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Dennis Holmes is a Surgical Oncologist in Glendale, California. Dr. Holmes is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, Mastectomy, and Lymphadenectomy. Dr. Holmes is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jain's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile